Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2010 Apr 8

PMID 20371660

Citations 70

Authors

Elisa Fabbrini

B Selma Mohammed

Kevin M Korenblat

Faidon Magkos

Jennifer McCrea

Bruce W Patterson

Samuel Klein

Affiliations

Soon will be listed here.

Abstract

Context: Nonalcoholic fatty liver disease is associated with risk factors for cardiovascular disease, particularly increased plasma triglyceride (TG) concentrations and insulin resistance. Fenofibrate and extended release nicotinic acid (Niaspan) are used to treat hypertriglyceridemia and can affect fatty acid oxidation and plasma free fatty acid concentrations, which influence intrahepatic triglyceride (IHTG) content and metabolic function.

Objective: The objective of the study was to determine the effects of fenofibrate and nicotinic acid therapy on IHTG content and cardiovascular risk factors. EXPERIMENTAL DESIGN AND MAIN OUTCOME MEASURES: We conducted a randomized, controlled trial to determine the effects of fenofibrate (8 wk, 200 mg/d), Niaspan (16 wk, 2000 mg/d), or placebo (8 wk) on IHTG content, very low-density lipoprotein (VLDL) kinetics, and insulin sensitivity.

Setting And Participants: Twenty-seven obese subjects with nonalcoholic fatty liver disease (body mass index 36 +/- 1 kg/m(2), IHTG 23 +/- 2%) were studied at Washington University.

Results: Neither fenofibrate nor Niaspan affected IHTG content, but both decreased plasma TG, VLDL-TG, and VLDL-apolipoprotein B concentrations (P < 0.05). Fenofibrate increased VLDL-TG clearance from plasma (33 to 54 ml/min; P < 0.05) but not VLDL-TG secretion. Niaspan decreased VLDL-TG secretion (27 to 15 micromol/min; P < 0.05) without affecting clearance. Both fenofibrate and Niaspan decreased VLDL-apolipoprotein B secretion (1.6 to 1.2 and 1.3 to 0.9 nmol/min, respectively; P < 0.05). Niaspan reduced hepatic, adipose tissue, and muscle insulin sensitivity (P < 0.05), whereas fenofibrate had no effect on insulin action.

Conclusions: Fenofibrate and Niaspan decrease plasma VLDL-TG concentration without altering IHTG content. However, the mechanism responsible for the change in VLDL-TG concentration is different for each drug; fenofibrate increases plasma VLDL-TG clearance, whereas nicotinic acid decreases VLDL-TG secretion.

Citing Articles

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Bril F, Berg G, Barchuk M, Nogueira J J Lipid Atheroscler. 2025; 14(1):5-29.

PMID: 39911965 PMC: 11791423. DOI: 10.12997/jla.2025.14.1.5.

The Interplay between Liver and Adipose Tissue in the Onset of Liver Diseases: Exploring the Role of Vitamin Deficiency.

Tattoli I, Mathew A, Verrienti A, Pallotta L, Severi C, Andreola F Cells. 2024; 13(19.

PMID: 39404394 PMC: 11475612. DOI: 10.3390/cells13191631.

Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment.

Vu H, Nguyen V, Ikenaga H, Matsubara T Biomedicines. 2024; 12(8).

PMID: 39200340 PMC: 11351628. DOI: 10.3390/biomedicines12081876.

Changes in glucose metabolism, C-reactive protein, and liver enzymes following intake of NAD + precursor supplementation: a systematic review and meta-regression analysis.

Sohouli M, Tavakoli S, Reis M, Hekmatdoost A, Guimaraes N Nutr Metab (Lond). 2024; 21(1):35.

PMID: 38915015 PMC: 11195006. DOI: 10.1186/s12986-024-00812-0.

The effect of niacin on inflammatory markers and adipokines: a systematic review and meta-analysis of interventional studies.

Rad E, Saboori S, Tammam J, Thondre P, Coe S Eur J Nutr. 2024; 63(6):2011-2024.

PMID: 38761279 PMC: 11377601. DOI: 10.1007/s00394-024-03425-8.

References

Kelly J, Lawson J, Campbell L, Storlien L, Jenkins A, Whitworth J . Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens. 2000; 14(9):567-72. DOI: 10.1038/sj.jhh.1001099. View

Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M . Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int. 2006; 26(5):613-20. DOI: 10.1111/j.1478-3231.2006.01265.x. View

Kissebah A, Alfarsi S, Adams P, Seed M, Folkard J, WYNN V . Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia: effects of 2,2-dimethyl, 5(2, 5-xylyoxy) valeric acid therapy. Atherosclerosis. 1976; 24(1-2):199-218. DOI: 10.1016/0021-9150(76)90076-9. View

Chen X, Iqbal N, Boden G . The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest. 1999; 103(3):365-72. PMC: 407905. DOI: 10.1172/JCI5479. View

Shepherd J, Packard C, Stewart J, Atmeh R, Clark R, Boag D . Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest. 1984; 74(6):2164-77. PMC: 425409. DOI: 10.1172/JCI111643. View

Gulick T, Cresci S, Caira T, Moore D, Kelly D . The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A. 1994; 91(23):11012-6. PMC: 45156. DOI: 10.1073/pnas.91.23.11012. View

Patterson B, Zhao G, Elias N, Hachey D, Klein S . Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. J Lipid Res. 1999; 40(11):2118-24. View

Grundy S, Mok H, ZECH L, Berman M . Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. 1981; 22(1):24-36. View

Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S . Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005; 48(4):634-42. DOI: 10.1007/s00125-005-1682-x. View

10.

Wang W, Basinger A, Neese R, Shane B, Myong S, Christiansen M . Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab. 2001; 280(3):E540-7. DOI: 10.1152/ajpendo.2001.280.3.E540. View

11.

Kirk E, Reeds D, Finck B, Mayurranjan S, Mayurranjan M, Patterson B . Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology. 2009; 136(5):1552-60. PMC: 2677125. DOI: 10.1053/j.gastro.2009.01.048. View

12.

Lambe K, Woodyatt N, Macdonald N, Chevalier S, Roberts R . Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett. 1999; 110(1-2):119-27. DOI: 10.1016/s0378-4274(99)00151-4. View

13.

Jin F, Kamanna V, Kashyap M . Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol. 1999; 19(4):1051-9. DOI: 10.1161/01.atv.19.4.1051. View

14.

Chang A, Smith M, Galecki A, Bloem C, Halter J . Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J Clin Endocrinol Metab. 2006; 91(9):3303-9. DOI: 10.1210/jc.2006-0913. View

15.

Carlson L, Oro L . The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand. 1962; 172:641-5. DOI: 10.1111/j.0954-6820.1962.tb07203.x. View

16.

Ganji S, Tavintharan S, Zhu D, Xing Y, Kamanna V, Kashyap M . Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004; 45(10):1835-45. DOI: 10.1194/jlr.M300403-JLR200. View

17.

Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R . Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005; 54(12):3541-6. DOI: 10.2337/diabetes.54.12.3541. View

18.

Garg A, Grundy S . Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990; 264(6):723-6. View

19.

Wang W, Basinger A, Neese R, Christiansen M, Hellerstein M . Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am J Physiol Endocrinol Metab. 2000; 279(1):E50-9. DOI: 10.1152/ajpendo.2000.279.1.E50. View

20.

Lewis G, Uffelman K, Szeto L, Weller B, Steiner G . Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995; 95(1):158-66. PMC: 295395. DOI: 10.1172/JCI117633. View